GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (BOM:524804) » Definitions » EV-to-EBITDA

Aurobindo Pharma (BOM:524804) EV-to-EBITDA : 10.21 (As of May. 25, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Aurobindo Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aurobindo Pharma's enterprise value is ₹704,390 Mil. Aurobindo Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was ₹69,007 Mil. Therefore, Aurobindo Pharma's EV-to-EBITDA for today is 10.21.

The historical rank and industry rank for Aurobindo Pharma's EV-to-EBITDA or its related term are showing as below:

BOM:524804' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.45   Med: 10.27   Max: 19.68
Current: 10.21

During the past 13 years, the highest EV-to-EBITDA of Aurobindo Pharma was 19.68. The lowest was 4.45. And the median was 10.27.

BOM:524804's EV-to-EBITDA is ranked better than
61.22% of 735 companies
in the Drug Manufacturers industry
Industry Median: 13.73 vs BOM:524804: 10.21

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-25), Aurobindo Pharma's stock price is ₹1196.45. Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹59.810. Therefore, Aurobindo Pharma's PE Ratio (TTM) for today is 20.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Aurobindo Pharma EV-to-EBITDA Historical Data

The historical data trend for Aurobindo Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma EV-to-EBITDA Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.70 6.07 8.35 7.38 10.44

Aurobindo Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.27 10.44 10.43 12.38 11.23

Competitive Comparison of Aurobindo Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's EV-to-EBITDA falls into.


;
;

Aurobindo Pharma EV-to-EBITDA Calculation

Aurobindo Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=704390.223/69007
=10.21

Aurobindo Pharma's current Enterprise Value is ₹704,390 Mil.
Aurobindo Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹69,007 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (BOM:524804) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Aurobindo Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1196.45/59.810
=20.00

Aurobindo Pharma's share price for today is ₹1196.45.
Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹59.810.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Aurobindo Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Aurobindo Pharma Headlines

No Headlines